News & Media

Boehringer Ingelheim News, Press Releases & Information

Quick access to the latest company news, including corporate, research & development and human pharmaceuticals for members of the media.

Press Release Subscription

Please submit the form below to receive press releases via email.

Information for...

PRESS RELEASE 14 Feb 2019 at 06:30

Boehringer Ingelheim and Lilly announce the CAROLINA^{^®} cardiovascular outcome trial of Tradjenta^{^®} met its primary endpoint of non-inferiority compared with glimepiride

Read more on
Boehringer Ingelheim and Lilly announce the CAROLINA^{^®} cardiovascular outcome trial of Tradjenta^{^®} met its primary endpoint of non-inferiority compared with glimepiride
- Press Release
PRESS RELEASE 29 Jan 2019 at 13:48

Everett Hoekstra Appointed President of Boehringer Ingelheim Animal Health USA Inc.

Read more on Everett Hoekstra Appointed President of Boehringer Ingelheim Animal Health USA Inc.
PRESS RELEASE 21 Jan 2019 at 08:00

The maker of HEARTGARD^{^®} Plus (ivermectin/pyrantel) launches initiative to combat rising incidence rates of heartworm disease

Read more on
The maker of HEARTGARD^{^®} Plus (ivermectin/pyrantel) launches initiative to combat rising incidence rates of heartworm disease
PRESS RELEASE 04 Jan 2019 at 07:00

Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target From Research Collaboration with Dicerna

Read more on Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target From Research Collaboration with Dicerna
PRESS RELEASE 03 Jan 2019 at 07:00

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

Read more on Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders
PRESS RELEASE 13 Dec 2018 at 06:30

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

Read more on Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease
PRESS RELEASE 12 Dec 2018 at 08:00

Boehringer Ingelheim Announces Winners of 2018 Champions of the Cause Awards

Read more on Boehringer Ingelheim Announces Winners of 2018 Champions of the Cause Awards
- Press Release
PRESS RELEASE 26 Nov 2018 at 14:00

Jardiance^{^®} Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway

Read more on
Jardiance^{^®} Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway
PRESS RELEASE 15 Nov 2018 at 06:30

Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies

Read more on Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies
PRESS RELEASE 05 Nov 2018 at 06:30

Initial results from EMPRISE real-world evidence study show Jardiance^{^®} was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Read more on
Initial results from EMPRISE real-world evidence study show Jardiance^{^®} was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
PRESS RELEASE 31 Oct 2018 at 11:00

Boehringer Ingelheim Announces Growth in the Bay Area

Read more on Boehringer Ingelheim Announces Growth in the Bay Area
- Press Release
PRESS RELEASE 22 Oct 2018 at 09:00

Real-world study shows sequencing of Gilotrif^{^®} followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

Read more on
Real-world study shows sequencing of Gilotrif^{^®} followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC
PRESS RELEASE 11 Oct 2018 at 08:00

FDA Approves Stiolto^{^®} Respimat^{^®} Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction

Read more on
FDA Approves Stiolto^{^®} Respimat^{^®} Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction
PRESS RELEASE 10 Oct 2018 at 08:00

New Internal Teat Sealant Added to Boehringer Ingelheim Dairy Mastitis Portfolio

Read more on New Internal Teat Sealant Added to Boehringer Ingelheim Dairy Mastitis Portfolio
PRESS RELEASE 10 Oct 2018 at 06:30

New analysis estimates the positive impact of Jardiance^{^®} on life expectancy in adults with type 2 diabetes and established cardiovascular disease

Read more on
New analysis estimates the positive impact of Jardiance^{^®} on life expectancy in adults with type 2 diabetes and established cardiovascular disease
PRESS RELEASE 04 Oct 2018 at 11:15

Boehringer Ingelheim and Lilly present full results of Tradjenta^{^®}’s CARMELINA^{^®} cardiovascular outcome trial

Read more on
Boehringer Ingelheim and Lilly present full results of Tradjenta^{^®}’s CARMELINA^{^®} cardiovascular outcome trial
- Press Release
PRESS RELEASE 04 Oct 2018 at 06:30

Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes

Read more on Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
- Press Release
PRESS RELEASE 02 Oct 2018 at 08:00

Introducing SEMINTRA® (telmisartan oral solution) —The First FDA-Approved Liquid Solution For Feline Hypertension

Read more on Introducing SEMINTRA® (telmisartan oral solution) —The First FDA-Approved Liquid Solution For Feline Hypertension
PRESS RELEASE 26 Sep 2018 at 09:00

Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC

Read more on Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
PRESS RELEASE 25 Sep 2018 at 09:15

Results of LUME-Meso trial in malignant pleural mesothelioma presented at the 19^th World Conference on Lung Cancer (WCLC 2018)

Read more on
Results of LUME-Meso trial in malignant pleural mesothelioma presented at the 19^th World Conference on Lung Cancer (WCLC 2018)

Search form

News & Media

Boehringer Ingelheim News, Press Releases & Information

Press Release Subscription